Latest news with #MindMed
Yahoo
7 days ago
- Business
- Yahoo
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today
Key Points Mind Medicine stock is a speculative play on future potential for psychedelics as therapeutic treatments. The stock has underperformed the S&P 500 over the last five years, but it has still delivered positive returns for investors. Mind Medicine is a risky investment, but it's possible the stock could deliver big wins for patient shareholders. 10 stocks we like better than Mind Medicine (MindMed) › Mind Medicine (NASDAQ: MNMD) is a clinical stage biotech company that's aiming to bring psychedelics and other compounds to market as forms of treatments for conditions including generalized anxiety disorder (GAD), major depressive disorder (MDD), and autism spectrum disorder (ASD). The business is still in a pre-revenue state and has a highly uncertain forward performance trajectory, but it's recently garnered an uptick in interest from investors thanks to encouraging clinical trial developments and indications that political and regulatory developments could give the company an easier path to commercialization. Owing in large part to its highly speculative outlook, Mind Medicine stock has seen periods of huge volatility over the last five years. Despite jumping roughly 35% over the last year of trading, the company's share price is actually down roughly 86% from its valuation high in the period. However, Mind Medicine still delivered substantial returns over the last five years. While the stock underperformed the S&P 500 index's total return of roughly 91% over the stretch, it still posted an 87% return over the 12 months ended Aug. 8. If you had invested $1,000 in the stock five years ago and held on to your shares, the position would now be worth roughly $1,875. Can Mind Medicine beat the market over the next five years? Mind Medicine stock is a very risky investment, but it does have avenues to significantly outperform the S&P 500 index over the next five years. The lead treatment in Mind Medicine's pipeline is a modified form of Lysergide D-tartrate, a form of LSD. While the idea of using psychedelics to treat anxiety and depressive disorders may seem unconventional, there is research that points to meaningful efficacy -- and Mind Medicine's early clinical results have supported continued research and trials. The company is set to release Phase III trial results for the treatment next year, and positive data could trigger the early stages of a strong run-up for the stock. Mind Medicine stock comes with a high risk profile, but shares could surge if the biotech specialist successfully brings a treatment to market. Should you buy stock in Mind Medicine (MindMed) right now? Before you buy stock in Mind Medicine (MindMed), consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Mind Medicine (MindMed) wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
08-08-2025
- Business
- Yahoo
1 Reason to Buy MindMed (MNMD)
Key Points The company must operate under strict regulations, as it is developing certain medicines based on psychedelic substances. Such compounds are currently illegal for sale or consumption throughout much of America. These 10 stocks could mint the next wave of millionaires › By their nature, clinical-stage biotech companies can be volatile investments. Even by that standard, MindMed (NASDAQ: MNMD) is quite a risky play; after all, a key element of its business strategy is to develop brain health medications based on compounds that are illegal on the federal level in the U.S. Threading the needle with the law For this reason, even a modest relaxation of current laws could really benefit MindMed. It isn't cheap or easy to operate within the many restrictions imposed due to the legal status of psychedelics (these can be used for medical research purposes, however the limits are strict). That's exacerbated by the fact that the company's pre-revenue just now. So all things being equal, the more it can put the brakes on cash burn, the longer it'll survive until it can (hopefully) get one of its investigational drugs approved and shipped to the market. At the moment, MindMed has sufficient resources to endure for at least a few years. At the end of March it had nearly $238 million in cash, cash equivalents, and short-term investments, which wasn't too much less than the previous quarter's $245 million. According to management, this plus monies for the expected achievement of certain milestones will be sufficient to fund operations into 2028 at least. Thaw in progress Happily, the decriminalization of psychedelics, for medical purposes anyway, enjoys plenty of support among the American public. A 2023 survey conducted by the University of California at Berkeley found that 61% of respondents approved of regulated therapeutic access to psychedelic-based medicines. Meanwhile, in recent years certain jurisdictions relaxed their restrictions on psychedelics. Several cities, such as Denver and Washington D.C., have decriminalized psilocybin (the psychoactive compound in "magic" mushrooms). I don't think full-blown decriminalization is around the corner in the United States. Rather, I think it'll be more an unhurried, stop-and-go process like that of marijuana law reform currently. As restrictions on its research ease, MindMed should be able to save some capital and extend its all-important runway. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $462,306!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $38,522!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $619,036!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. 1 Reason to Buy MindMed (MNMD) was originally published by The Motley Fool
National Post
31-07-2025
- Business
- National Post
MindMed Reports Q2 2025 Financial Results and Business Updates
Article content –Strong enrollment continues in all three Phase 3 trials of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD)– Article content –Data from the Phase 3 Voyage trial in GAD anticipated in 1H 2026 and data from the Phase 3 Panorama trial in GAD and Phase 3 Emerge trial in MDD anticipated in 2H 2026– Article content Article content –Strengthened leadership team with appointment of Brandi L. Roberts as Chief Financial Officer– Article content –Conference call scheduled today at 4:30 p.m. EDT– Article content NEW YORK — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the 'Company' or 'MindMed'), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its second quarter 2025 financial results and provided an update on business highlights. 'We continue making significant progress across all three of our pivotal Phase 3 trials evaluating MM120 ODT in GAD and MDD, with ongoing enthusiasm from both trial sites and participants driving strong enrollment,' said Rob Barrow, Chief Executive Officer of MindMed. 'We remain on track to report topline data from our Phase 3 Voyage trial in the first half of 2026, followed by Panorama and Emerge in the second half of the year. In parallel, we are advancing our commercial strategy and have continued to strengthen our leadership team with the appointment of Brandi Roberts as Chief Financial Officer. With our clearly defined regulatory strategy, disciplined operational execution, and strong balance sheet, we are well-positioned to advance MM120 ODT as a potential best-in-class therapeutic option for the treatment of GAD and MDD.' Article content Business Highlights Article content Progressing Pivotal Trials: Strong enrollment continues across all three MM120 ODT Phase 3 trials: Voyage and Panorama in GAD and Emerge in MDD. The continued execution reinforces the Company's targeted trial timelines and progress in preparing for a potential NDA filing. Strengthened Leadership for Growth: Appointed Brandi L. Roberts as Chief Financial Officer. Ms. Roberts brings more than 25 years of financial leadership experience within the life sciences industry. As a member of the executive team, she leads all aspects of the Company's financial strategy, capital planning, accounting, investor relations and information technology. Article content MM120 ODT (lysergide D-tartrate) for GAD Article content Enrollment is on track in the Phase 3 Voyage study of MM120 ODT for the treatment of GAD. Voyage is expected to enroll approximately 200 participants in the U.S. who will be randomized 1:1 to receive MM120 ODT 100 µg or placebo. Topline data from the 12-week double-blind period (Part A) is anticipated in the first half of 2026. Enrollment is on track in the Panorama study, the Company's second Phase 3 study of MM120 ODT for the treatment of GAD. Panorama is expected to enroll approximately 250 participants (randomized 2:1:2 to receive MM120 ODT 100 µg, MM120 ODT 50 µg or placebo) in the U.S. and Europe. Topline data from the 12-week double-blind period (Part A) is anticipated in the second half of 2026. Article content MM120 (lysergide D-tartrate) for MDD Article content Enrollment is on track in the Phase 3 Emerge study of M120 ODT for the treatment of MDD. Emerge is expected to enroll 140 participants (randomized 1:1 to receive MM120 ODT 100 µg or placebo). Topline data from the 12-week double-blinded period (Part A) is anticipated in the second half of 2026. The Company expects to conduct a second Phase 3 registrational study in MDD, with the study design and timing to be informed by the progress of Emerge and additional regulatory discussions. Article content MM402 (R(-)-MDMA) for Autism Spectrum Disorder (ASD) Article content Completed a Phase 1 study of MM402, a single-ascending dose study in adult healthy volunteers. The study characterized the tolerability, pharmacokinetics and pharmacodynamics of MM402. The Company expects to initiate further studies of MM402 to assess its potential efficacy for the treatment of ASD. Article content Cash Balance. Article content As of June 30, 2025, MindMed had cash, cash equivalents and investments totaling $237.9 million compared to $245.5 million as of March 31, 2025. Article content Based on the Company's current operating plan and anticipated R&D milestones, the Company believes that its cash, cash equivalents and investments as of June 30, 2025 will be sufficient to fund the Company's operations into 2027 and at least 12 months beyond its first Phase 3 topline data readout for MM120 ODT in GAD. Article content Research and Development (R&D). Article content R&D expenses were $29.8 million for the quarter ended June 30, 2025, compared to $14.6 million for the quarter ended June 30, 2024, an increase of $15.2 million. The net increase of $15.2 million was primarily related to increases of $14.5 million related to our MM120 ODT program, $1.5 million in internal personnel costs as a result of increased headcount, and $0.2 million related to preclinical activities, offset by a decrease of $1.0 million in MM402 program expenses based on the timing of studies. Article content General and Administrative (G&A). Article content G&A expenses were $11.1 million for the quarter ended June 30, 2025, compared to $9.8 million for the quarter ended June 30, 2024, an increase of $1.3 million. The increase was primarily related to increases in personnel costs as a result of increased headcount. Article content Net Loss. Article content Net loss for the quarter ended June 30, 2025, was $42.7 million, compared to $5.9 million for the same period in 2024, a decrease of $36.8 million. The decrease was primarily due to increases in operating expenses of $16.4 million, changes in the fair value of warrants issued in our September 2022 underwritten offering of $15.6 million, the absence of a $2.5 million gain on extinguishment of contribution payable from 2024 and increased interest expense related primarily to the amendment of our credit facility of $1.8 million. Article content Conference Call and Webcast Reminder Article content MindMed management will host a webcast at 4:30 p.m. EDT today to provide a corporate update and review the Company's second quarter 2025 financial results, and business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time. Article content About MM120 Orally Disintegrating Tablet (ODT) Article content MM120 ODT (lysergide D-tartrate or LSD) is a synthetic ergotamine belonging to the group of classic, or serotonergic, psychedelics which acts as a partial agonist at human serotonin-2A (5-HT2A) receptors. MM120 ODT is MindMed's proprietary and pharmaceutically optimized form of LSD. MM120 ODT is an advanced formulation incorporating Catalent's Zydis® ODT fast-dissolve technology which has a unique clinical profile with more rapid absorption, improved bioavailability and reduced gastrointestinal side effects. MindMed is developing MM120, the tartrate salt form of lysergide, for generalized anxiety disorder (GAD), major depressive disorder (MDD), and is exploring its potential applications in other serious brain health disorders. Article content About MM402 Article content MM402 is the Company's proprietary form of R(-)-MDMA (rectus-3,4-methylenedioxymethamphetamine), being developed for the treatment of core symptoms of Autism Spectrum Disorder (ASD). MDMA is a synthetic molecule that is often referred to as an empathogen because it is reported to increase feelings of connectedness and compassion. Preclinical studies of R(-)-MDMA demonstrate its acute pro-social and empathogenic effects, while its diminished dopaminergic activity suggest that it has the potential to exhibit less stimulant activity, neurotoxicity, hyperthermia and abuse liability compared to racemic MDMA or the S(+)-enantiomer. Article content About MindMed Article content MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD. Article content Forward-Looking Statements Article content Certain statements in this news release related to the Company constitute 'forward-looking information' within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'will', 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe', 'potential' or 'continue', or the negative thereof or similar variations. Forward-looking information in this news release includes, but is not limited to, statements regarding the Company's anticipated topline readout (Part A results) for the Phase 3 Voyage study of MM120 ODT in GAD in the first half of 2026; the Company's anticipated topline readout (Part A results) for the Phase 3 Panorama study for MM120 ODT in GAD in the second half of 2026; the Company's anticipated topline readout (Part A results) for the Phase 3 Emerge study for MM120 ODT in MDD in the second half of 2026; the Company's plans to conduct a second Phase 3 study in MDD; the Company's expectations regarding the enrollment for each of the Voyage, Panorama and Emerge studies; the Company's beliefs regarding potential benefits of its product candidates; the Company's expectation to conduct further studies of MM402; the Company's expectation that its cash, cash equivalents and investments will fund operations into 2027; the Company's expectation that its cash runway will extend at least 12 months beyond its first Phase 3 topline data readout for MM120 ODT in GAD; and potential additional indications for MM120 ODT and MM402. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; compliance with laws and regulations; legislative and regulatory developments, including decisions by the Drug Enforcement Administration and states to reschedule any of our product candidates, if approved, containing Schedule I controlled substances, before they may be legally marketed in the U.S.; difficulty associated with research and development; risks associated with clinical studies or studies; heightened regulatory scrutiny; early stage product development; clinical study risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; ability to maintain effective patent rights and other intellectual property protection; as well as those risk factors discussed or referred to herein and the risks, uncertainties and other factors described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 under headings such as 'Special Note Regarding Forward-Looking Statements,' and 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and other filings and furnishings made by the Company with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, changes in expectations or otherwise. Article content Mind Medicine (MindMed) Inc. Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Three Months Ended June 30, Six Months Ended June 30, (in thousands, except share and per share amounts) 2025 2024 2025 2024 Operating expenses: Research and development $ 29,809 $ 14,645 $ 53,166 $ 26,350 General and administrative 11,094 9,813 19,896 20,312 Total operating expenses 40,903 24,458 73,062 46,662 Loss from operations (40,903 ) (24,458 ) (73,062 ) (46,662 ) Other income/(expense): Interest income 2,774 3,116 5,207 4,772 Interest expense (2,338 ) (466 ) (2,940 ) (900 ) Foreign exchange loss, net (49 ) (32 ) (68 ) (557 ) Change in fair value of 2022 USD Financing Warrants (2,228 ) 13,445 4,771 (19,448 ) Gain on extinguishment of contribution payable — 2,541 — 2,541 Total other income/(expense) (1,841 ) 18,604 6,970 (13,592 ) Net loss (42,744 ) (5,854 ) (66,092 ) (60,254 ) Other comprehensive loss Unrealized gain on investments 36 — 46 — Gain/(loss) on foreign currency translation (31 ) (3 ) (58 ) 490 Comprehensive loss $ (42,739 ) $ (5,857 ) $ (66,104 ) $ (59,764 ) Net loss per common share, basic $ (0.50 ) $ (0.08 ) $ (0.78 ) $ (1.01 ) Net loss per common share, diluted $ (0.50 ) $ (0.26 ) $ (0.81 ) $ (1.01 ) Article content Article content Article content Article content Article content Contacts Article content For Media: Article content Article content Article content
Globe and Mail
24-07-2025
- Business
- Globe and Mail
MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the 'Company' or 'MindMed'), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, July 31, 2025 to report financial results for the first quarter ended June 30, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time. About MindMed MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.
National Post
24-07-2025
- Business
- National Post
MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025
Article content NEW YORK — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the 'Company' or 'MindMed'), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, July 31, 2025 to report financial results for the first quarter ended June 30, 2025, and discuss recent business updates. Article content Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time. Article content Article content About MindMed Article content MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD. Article content Article content Article content Article content Article content
